MKMehran Kouchek

Mehran Kouchek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mehran Kouchek has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating the Effect of Hypertonic Saline in Critically Ill Patients with Generalized Edema: A Randomized, Open-Label, Blinded Outcome Clinical Trial

    by Mohammad Sistanizad, Sara Salarian, Samin Salehijazi, Niloufar Taherpour, Mehran Kouchek, Mir Mohammad Miri, Seyed Pouzhia Shojaei, Saeed Mohammad Soleymani

    Background: It is known that in certain situations, such as heart failure, hypertonic saline can facilitate fluid removal by diuretics — especially loop diuretics — which improve the pathophysiological condition and reduce symptoms in hospitalized ICU patients. Objectives: Our study aimed to evaluate the effect of adding 5% NaCl solution to loop diuretics in managing edema and increasing urine volume in critically ill patients with edema. Methods: This study was designed as a two-arm, parallel-group, randomized, open-label clinical trial with blinded outcome assessment. Critically ill adult patients with 2+ edema or greater were included in the study and randomly allocated into two groups: Intervention and control. In the intervention group, patients received 20 mg of furosemide plus 50 mL of hypertonic saline; in the control group, patients received 20 mg of furosemide plus 50 mL of normal saline. Both were infused over 30 minutes, three times daily for 48 hours. Changes in urine output and edema were assessed. Results: Twenty-eight patients were recruited and randomly allocated into intervention and control arms, with 14 patients in each group. The two groups were similar in terms of baseline demographic and laboratory characteristics. Urine volume increased significantly in both groups at 24 and 48 hours after the intervention; however, there were no statistically significant differences in edema changes, total urine output, or changes in urine volume between the two groups at 24 and 48 hours post-enrollment. After the trial, the percentage of patients with 4+ edema in the intervention group decreased from 21.43% to 0%, and in the control group from 7.14% to 0%. Edema graded 1+ increased from 0% to 28.57% and 42.86% in the intervention and control groups, respectively. Additionally, urine output in the control group increased from 1,550 mL to 4,450 mL per day, and in the intervention group from 2,025 mL to 3,600 mL per day, 48 hours after the start of the study. Conclusions: The results showed that critically ill patients hospitalized in the intensive care unit (ICU) with edema respond well to diuretic therapy. However, adding hypertonic saline to loop diuretics does not demonstrate a synergistic effect in these patients. Further studies with a larger sample size or a higher dose of saline and diuretic are recommended.

  • Open Access

    Demographic study of patients' mortality rate before and after the COVID‐19 outbreak: A cross‐sectional study

    by Mehran Kouchek, Kamran Aghakhani, Azadeh Memarian

    Background and Aim: To better guide the health policies, it is essential to clarify the socio‐demographic and clinical risk factors affecting the mortality rate of patients with coronavirus disease 2019 (COVID‐19). Objective: The purpose of this project is to separate hospital mortality statistics into different groups, which will definitely help in planning to reduce the mortality rate. As well, we aimed to compare factors involved in COVID‐19 death between the period before and after its outbreak. Methods: This cross‐sectional study was performed based on all death certificates of archived records in Rasool Akram Hospital during the years 2018 and the first half of 2019. A checklist was completed based on the variables, including death cases by time, gender, age, duration of hospitalization, department of place and time of death, cause of death, cases referred to forensic medicine, information of the patient, including educational and occupational level and birth certificate issuing city, neonatal death, and IUFD, classification of diseases according to the provided version of ICD 10 (international classification of diseases 10th edition). Results: A number of 2632 deceased patients were included in this study, 1511 (57.4%) patients who died before the start of the COVID‐19 outbreak, and 1121 (42.6%) patients died in the hospital after the start of this pandemic. There were statistically significant differences in gender (higher prevalence of males), increased average age, lower occupational status, decreased number of infants, increased cause of death due to COVID‐19 and increased hospitalization in Royal ICU in dead patients ( p < 0.05). Conclusion: The findings show that the elderly cases are more at risk of COVID‐19 mortality than other age groups, which needs more attention to this group of society and clarifies other epidemiological factors, as well as clinicopathological and public healthcare practices.


  • Open Access

    Evaluation of the FAST HUG implementation effect on the mortality and length of stay in admitted patient in Intensive Care Unit (ICU) of a hospital

    by Mehran Kouchek, Behnam Arabzadeh, Navid Nooraei, Mansour Fathi, Mir Mohammad Miri

    Objective: We aimed to determine new version of the FAST HUG implementation effect on the mortality and length of stay in admitted patient in Intensive Care Unit (ICU) of a hospital. Methods: We conducted a prospective cohort study on 406 patients who admitted in medical and surgical ICU of Imam Hossein Hospital of Tehran province in Iran from July 1, 2022, to September 30, 2022. We identified predictors of ICU mortality by logistic regression model, predictors of 28-day mortality/re-hospitalization/recovery by generalized ordered logit model, predictors of length of stay (LOS) by linear regression, predictors of mechanical ventilation by generalized ordered logit and predictors of SOFA score by hurdle model. Results: This mnemonic had protective impact (OR = 0.56, P-value = 0.01) on the 28-days mortality. One unit increase in mean of FAST HUG score had a preventive effect on the outcome of death (OR = 0.21). Surgical admission type (Coefficient = –3.24, P-value = 0.00) and FAST HUG implementation (Coefficient =1.58, P-value= 0.0) were strongest factors on the LOS. Conclusion: Our study results approved the importance of the FAST HUG implementation on the decrease of patient mortality in ICU and 28 days after discharge. Additionally, this checklist had a statistically significant role in declining SOFA scores in ICU patients.


  • Open Access

    Oral Melatonin for Colistin-induced Nephrotoxicity Reduction in Intensive Care Unit: A Randomized Placebo Controlled Clinical Trial

    by Seyedpouzhia Shojaei, Mohammad Torabi, Mohammad Sistanizad, Mehran Kouchek, Mir Mohammad Miri, Sara Salarian, Padideh Ansar

    Background: Colistin is a drug of choice against multidrug-resistance (MDR) bacteria. The most important side effect of colistin is nephrotoxicity, observed in 20 - 54% of patients. According to the studies that examined its antioxidant effect, it can reduce the kidney toxicity of various drugs, including colistin. Objectives: This study aimed to investigate melatonin's effect on reducing colistin-induced kidney toxicity to use this drug with fewer complications. Methods: This double-blind, randomized clinical trials with two groups involved 56 critically ill adults infected by MDR bacteria. The intervention group received 3 mg of oral melatonin simultaneously with intravenous colistin, which continued until the end of the treatment. The control group received placebo orally with IV colistin. We measured urine volume, blood creatinine, and blood urea nitrogen (BUN) daily and determined the patients with renal failure using the KDIGO guideline. STATA software analyzed data with a P-value of less than 0.05 as the significance level. Results: Data obtained from recipients were analyzed for age (P-value = 0.357), gender (P-value = 0.945), weight (P-value = 0.438), APACHE score (P-value = 0.162). We did not observe significant difference in acute kidney injury (AKI) criteria between the two groups. Compared to the control group, melatonin did not decrease blood creatinine (P-value = 0.110) and BUN (P-value = 0.567) and, made no change of urinary volume (P-value = 0.913). There was no decrease in kidney failure in the intervention group compared to the control group. As a result, we did not find a significant difference in outcome of the two groups. Conclusions: We did not reveal any significant difference in the AKI criteria including blood creatinine, BUN, and daily urine volume with the addition of melatonin in participants receiving colistin; However, no complication was observed in the intervention group who received melatonin.


  • Open Access

    Effect of High-dose Vitamin D on IL-1β Blood Level in Patients with Moderate Stroke: A Randomized Clinical Trial

    by Mehran Kouchek, Seyedpouzhia Shojaei, Saied Amniati, Mehran Ghaffari, Sara Salarian, Mir Mohammad Miri, Niloufar Taherpour, Farnoosh Masbough, Mohammad Sistanizad

    Background: Vitamin D has neuroprotective and anti-inflammatory effects in stroke patients, but its effect on pro-inflammatory and inflammatory cytokines, especially IL-1, has been investigated in a few trials. Objectives: This study aimed to determine the effect of prescribing a high dose of vitamin D on the anti-inflammatory parameters, short-term and long-term prognosis of patients with ischemic stroke. Methods: This randomized clinical trial was performed on 42 patients randomly divided into two equal groups of 21 in Imam Hussein Hospital. The patients were allocated through block randomization methods to receive 300,000 units of vitamin D (intramuscularly) or not receive it as a control group. Age, gender, and clinical and laboratory information were recorded. The stroke severity was calculated according to the National Institute of Health Stroke Scale (NIHSS) at the beginning of hospitalization and upon hospital discharge. The 3-month prognosis of the patients was recorded according to the Barthel criteria three months after the stroke. Vitamin D3 levels were recorded before and after injection, while the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were assessed on the first day and for 7 consecutive days after hospitalization. All statistical analyses were performed using STATA version 14. A P-value < 0.05 was considered significant. Results: The mean age of the patients was 61.45 ± 4.74 years. There were 18 female (42.86%) and 24 male patients (57.14%). In the vitamin D group, the mean IL-1 decreased compared to before the intervention (-23.60 ± 103.83), but this decrease was not statistically significant (P = 0.070). In addition, the changes in IL-1 after the intervention were statistically different between the two groups (mean difference of -23.60 ± 103.83 in the vitamin D group vs. 15.96 ± 9.64 in the control group). The mean IL-6 decreased in both groups after the intervention compared to before, although these changes were not statistically significant (P > 0.05). In the group receiving vitamin D compared to the control group, the mean NLR decreased by about 2 units, the PLR decreased by about 10 units, and the NIHSS score decreased by about one unit during the study. However, these changes were not statistically significant (P > 0.05). Conclusions: A high dose of vitamin D can improve the NIHSS score and decrease IL-1 and IL-6, although these changes were not statistically significant. The mean NLR and PLR decreased after using high-dose vitamin D.


  • Open Access

    Demographic and Clinical Profiles Including Comorbidities in Hospitalized Patients Under 18 Years of Age with COVID-19

    by Azadeh Memarian, Seyed Khosro Ghasempouri, Mehran Kouchek, Behnam Sobouti, Kamran Aghakhani

    Objectives: This study was aimed to evaluate the various demographic and clinical characteristics in hospitalized children with COVID-19 as well as their comorbidities. Methods: This cross-sectional study evaluated a total of 809 hospitalized COVID-19 patients under 18 years of age in the referral university based Ali-Asghar Hospital in 2020. Demographic and clinical characteristics of patients were extracted from the archived records and data analysis was performed using SPSS software version 26. Results: The mean age of patients was 4.1 years and the higher percentage of patients (57%) were male. The most common symptoms of COVID-19 in children were fever, cough, and diarrhea. As well, the most common symptoms in 22.1% of patients admitted to the intensive care unit (ICU) were gastrointestinal (GI) symptoms (79%), fever (62.6%), and respiratory distress (53.6%), respectively. The majority of patients were in the age group less than one year (52%) and mortality rate was 6.3% in total and 10% in children with underlying disease. Besides, the mortality rate of intubated cases was 13 times higher. Conclusion: The findings of present study showed that COVID-19 in children was associated with various clinicopathological manifestations. Underlying disease including respiratory distress, cancer, and kidney disease as well as GI symptoms might be guided predicting the hospitalized cases in ICU. Newborns less than one year of age are exposed to severe COVID-19 infection which is associated with higher mortality rate and it should be given special attention in the early diagnosis and management of the COVID-19 disease.

  • Open Access

    Bromhexine for Post-exposure COVID-19 Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial

    by Ramin Tolouian, Omid Moradi, Zuber D. Mulla, Shadi Ziaie, Mehrdad Haghighi, Hadi Esmaily, Hossein Amini, Rezvan Hassanpour, Elham Poorheidar, Mehran Kouchek, et al.

    Background: Limited medications are available for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) infection. Whether bromhexine can prevent or mitigate symptomatic infection after virus exposure is undetermined. Objectives: We aimed to evaluate bromhexine's effect on preventing COVID-19 after close contact exposure. Methods: A multi-center randomized, double-blind, placebo-controlled clinical trial was conducted on 372 adults (≥ 18 years) who had close contact within four days with a household member with confirmed COVID-19. They were randomly assigned to receive bromhexine 8 mg (n = 187) or placebo (n = 185) three times a day for two weeks. The primary outcome was the incidence of symptomatic COVID-19. Secondary outcomes included hospitalization or death, confirmed COVID-19 by Polymerase Chain Reaction (PCR) in symptomatic patients, and adverse drug reactions. Results: The incidence of symptomatic COVID-19 was significantly lower in individuals who received bromhexine than in those who received the placebo (16 [8.6%] vs. 34 [18.4%], relative risk = 0.47, P = 0.005). PCR confirmation was reported in 13 (7.0%) and 26 (14.1%) individuals in the bromhexine and placebo groups, respectively (P = 0.025), with a relative risk reduction of 50%. The hospitalization rate, death, and medication side effects did not vary significantly between the bromhexine and placebo arms. Conclusions: Bromhexine is an effective, non-invasive, affordable agent with a low side-effect profile to prevent symptomatic COVID-19. Early use of bromhexine potentially provides another layer of protection; hence, it can play a role in controlling the pandemic.


  • Open Access

    Impact of a High-protein Nutritional Intake on the Clinical Outcome of the Neurocritical Patients

    by Forouzan Ahmadpour, Mehran Kouchak, Mir Mohammad Miri, Sara Salarian, Seyedpouzhia Shojaei, Kiana Ramezanzadeh, Paria Rezapour, Mohammad Sistanizad

    Disease-related malnutrition of neurocritical illness harms its treatment, which increases the mortality rate. The aim of this study was evaluating the effect of a high protein diet on the dietary factors, clinical outcome, and mortality rate of neurocritical patients. In a randomized controlled trial, 15 neurocritical patients were recruited in each group. The patients in the intervention and control groups received high protein and conventional protein regimens, respectively. The Clinical Extended Glasgow Outcome Scale (GOSE) measured at one, two, and three months later. Acute Physiology and Chronic Health Evaluation II (APACHE-II) score, Glasgow Coma Scale, the serum level of transthyretin (TTR) on the first, 3rd and fifth days of admission, and nitrogen balance (NB) at the baseline and fifth day of the study were recorded. Thirty patients, 15 in each group, entered into the study. There was no statistically significant difference in the baseline characteristics of the patients between the two groups of the study. The 28-days-mortality rate in the intervention and control group were 33.3% (n = 5) and 73.3% (n = 11), P-value = 0.034, respectively. The GOSE scores were higher in the patients who received a high protein diet, and lower in the patients with lower baseline TTR, higher APACHE-II score, older age, and a baseline negative nitrogen balance. The high protein diet may decrease the mortality rate, and improve the clinical outcome of neurocritical patients. The baseline TTR level, APACHE II score, and NB are prognostic factors for the prediction of the GOSE in neurocritical patients.


  • Open Access

    Comparison of Intravenous Ampicillin-sulbactam Plus Nebulized Colistin with Intravenous Colistin Plus Nebulized Colistin in Treatment of Ventilator Associated Pneumonia Caused by Multi Drug Resistant Acinetobacter Baumannii: Randomized Open Label Trial

    by Elham Pourheidar, Mehrdad Haghighi, Mehran Kouchek, Mir Mohammad Miri, Seyedpouzhia Shojaei, Sara Salarian, Rezvan Hassanpour, Mohammad Sistanizada

    The purpose of this study was evaluating the efficacy and safety of intravenous (IV) ampicillin-sulbactam plus nebulized colistin in the treatment of Ventilator-Associated Pneumonia (VAP) caused by MDR Acinetobacter (MDRA) in ICU patients as an alternative to IV plus nebulized colistin. In this single-blinded RCT, one group received IV colistin and another group IV ampicillin-sulbactam (16 and 12 patients from total 28 patients, respectively) for 14 days or since clinical response. Both groups received nebulized colistin by mesh nebulizer. There were no statistically significant differences between the 2 groups in baseline characteristics and previous antibiotic therapy. In follow up period, no significant difference was observed between 2 groups in rate of microbiological eradication, clinical signs of VAP improvement, survival rate and length of hospital as well as ICU stays. Although we have found no significant differences in Acute Kidney Injury (AKI) incidence between two groups, comparison of cumulative patient-days with stages 2 and 3 AKI with days with no or stage 1 AKI, according to AKIN criteria, revealed significant difference in IV colistin versus IV ampicillin-sulbactam group (p = 0.013). The results demonstrated that the high dose IV ampicillin-sulbactam plus nebulized colistin regimen has comparable efficacy with IV plus nebulized colistin in the treatment of VAP caused by MDRA, with sensitivity to colistin only, with probably lower incidence of kidney injury.


  • Open Access

    Effect of High-Dose Vitamin D on Duration of Mechanical Ventilation in ICU Patients

    by Mir Mohammad Miri, Mehran Kouchek, Alireza Rahat Dahmardeh, Mohammad Sistanizad

    The relationship of vitamin D3 with the duration of mechanical ventilation and mortality is still unknown. Therefore, this study aimed to determine the effect of using high-dose vitamin D on the duration of mechanical ventilation among the patients admitted to the intensive care unit. The current double-blinded clinical trial was performed on 44 mechanically ventilated, adult patients. Using permuted block randomization, the patients were recruited in intervention and placebo arms. In the placebo group, four patients were excluded due to death before 72 h. The vitamin D level was measured in both groups on entrance and 7th day of the study. The intervention and placebo groups received intramuscular injection of 300000 IU vitamin D and identical placebo, respectively. SOFA and CPIS score were evaluated daily for 7 days and on 14th and 28th days of the study. Also duration of mechanical ventilation and mortality rate were recorded. Fourteen males and 8 females were recruited in the intervention group, as well as 13 males and 5 females in the control group. There was no significant difference in baseline characteristics of the patients including gender and age. The mean duration of the mechanical ventilation was 17.63 ± 14 days in the intervention group versus 27.72 ± 22.48 days in the control group (p = 0.06). Mortality rate in control and intervention groups was 61.1% versus 36.3% (p = 0.00), respectively. Administration of high-dose vitamin D could reduce mortality in mechanically ventilated patients. Despite decrease of 10 days in duration of mechanical ventilation, the difference was not statistically significant. Larger studies are recommended.